Navigation Links
Neuronetrix Announces Preliminary Alzheimer's Study Results at the Society for Neuroscience Conference
Date:12/8/2008

LOUISVILLE, Ky., Dec. 8 /PRNewswire/ -- Last week, at the Society for Neuroscience Conference in Washington DC, Neuronetrix announced preliminary results from a clinical study of their COGNISION(TM) System to diagnose Alzheimer's disease. The study was performed with Alzheimer's patients at the University of Kentucky's Sanders-Brown Center for Aging.

The COGNISION(TM) System uses event-related potentials (ERP) to record brain activity while the patient listens to a sequence of sounds. Subjects with Alzheimer's process auditory information differently than healthy individuals and that difference can be detected with the test.

The ability of the ERP method to diagnose Alzheimer's disease has been demonstrated in scientific studies at several research laboratories around the world. In a scientific paper published in 2007, Neuronetrix collaborators Drs. Robi Polikar, et al, reported that their ERP classification accuracy "exceeded that of the trained community clinic physicians, and closely approached the gold standard performance of the university hospital-based clinic evaluation."

This phase of the study was primarily performed to evaluate the COGNISION(TM) System in a real-world clinical setting to test ease of use, patient tolerance, and most importantly, data quality.

"Clinical usability and technical performance were major milestones in our study at the Sanders-Brown Center." "The system exceeded our expectations in terms of data quality and we demonstrated the test could be efficiently performed on real Alzheimer's patients." K.C. Fadem, Neuronetrix, Inc.

The next clinical study phase for Neuronetrix will be to test the COGNISION(TM) System in a multi-center trial on patients who have been diagnosed with Alzheimer's disease using a rigorous diagnostic protocol. This protocol will be similar to that used in the Alzheimer's Disease Neuroimaging Initiative (ADNI), a large international study sponsored by the US National Institutes of Health (NIH).

The ADNI protocol uses psychometric testing, magnetic resonance imaging (MRI), and cerebrospinal fluid analysis (CSF) to accurately characterize several aspects of Alzheimer's disease. Neuronetrix will use these same tests to correlate with the COGNISION(TM) ERP results.

"We want to compare our COGNISION(TM) System with the most advanced diagnostic methods possible to clearly demonstrate the system's capabilities." Dr. John Barker, Chairman, Neuronetrix, Inc.

Neuronetrix is currently working with several NIH Center's of Excellence in the US and a center in Europe to organize the study which is expected to begin in the first quarter of 2009.

About Alzheimer's Disease

Alzheimer's disease is a chronic neurodegenerative disease of the brain which eventually leads to death. Today, Alzheimer's disease affects over 5 million Americans with 500,000 new cases reported each year. The Center for Disease Control recently reported that Alzheimer's disease is the 7th leading cause of death in the US. Those affected by Alzheimer's disease survive only about half as long as those unaffected and of similar age. In 2005, Medicare/Medicaid spending totaled $112 billion on beneficiaries with Alzheimer's and other dementias.

For information: http://www.neuronetrix.com .


'/>"/>
SOURCE Neuronetrix, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
4. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
5. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
6. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
7. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
8. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
9. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
10. Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights
11. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/25/2017)... 25, 2017  EpiVax, Inc., a leader in ... immune-engineering today announced the launch of EpiVax Oncology ... personalized therapeutic cancer vaccines. EpiVax has provided $500,000 ... to enabling technologies to the new precision immunotherapy ... EpiVax Oncology as Chief Executive Officer. Gad brings ...
(Date:9/19/2017)... , Sept. 19, 2017 HistoSonics, Inc., a venture-backed medical device company developing a ... targeted tissues, announced three leadership team developments today:   ... ... ... Veteran medical device executive Josh Stopek , ...
(Date:9/13/2017)...   OrthoAtlanta has been named the official orthopedic ... (AFHC) for the 2018 College Football Playoff (CFP) National Championship ... Stadium in Atlanta, Georgia . OrthoAtlanta is ... campaign, participating in many activities leading up to, and including ... ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... October 13, 2017 , ... The Visiting Nurse Association (VNA) of ... collection of specialty vendors and unique items from across the nation, this holiday-themed event ... wellness services offered by the VNA. The boutique will be open Saturday, November ...
(Date:10/13/2017)... ... October 13, 2017 , ... Talented host, ... lowdown on sciatica in a new episode of "Success Files," which is an ... and innovation and investigates each subject in-depth with passion and integrity. , Sciatica ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... for healthcare compliance program management, will showcase a range of technology and learning ... Assisted Living (NCAL) Convention and Expo to be held October 14–18, 2017 at ...
(Date:10/12/2017)... Fla. (PRWEB) , ... October 12, 2017 , ... IsoComforter, ... therapy products, announced today the introduction of an innovative new design of the shoulder ... pad so you get maximum comfort while controlling your pain while using cold therapy. ...
(Date:10/12/2017)... ... 2017 , ... Dr. Parsa Mohebi, the Los Angeles based ... the newly revamped Cosmetic Town journal section, featuring articles written by ... as Follicular Unit Extraction (FUE). , Dr. Mohebi says “I enjoy ...
Breaking Medicine News(10 mins):